Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026

Get updates on Theralase Technologies Inc. delivered in your email.

Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Sample size : Accelerated versus regular pathway

View:

Post by N0taP00p on Apr 15, 2023 10:27pm

Sample size : Accelerated versus regular pathway

I was trying to understand if a small sample size was a detriment to oncology drug approvals by the FDA. If you search on the following text "Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018", you will find this in the article:... " we found that accelerated pathway approvals are based on significantly more single-arm studies with small sample sizes and surrogate primary endpoints. However, effect size was not different between the pathways".

Shout out to Cancerslayer. This was what you implied also, I think. We should know "soon" (a word that I've begun to dissect for deeper meanings of late). Sad.

398

Comment

Comment by Rumpl3StiltSkin on Apr 16, 2023 10:39am

Poop, As a long time holder of this stock, I've never been more sure of a great outcome, $$$$$. And it will, mostly, hapen in '23. IMO. :-)

117

Comment

Theralase Technologies Inc.

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

Connect with V.TLT

INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

FACT SHEET

The Watchlist

< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
Best-in-class treatment for NMIBC (according to interim clinical data)
NMIBC (Non-Muscle-Invasive Bladder Cancer)

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250

Become a member today, It's free!

Sign In

Send my password